Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23464917 | 0.86 | CHRM5 (0.75) | CHRM5CHRM3ALDH1A1TDP1KDM4E | |
| SCHEMBL18743787 | 0.84 | CHRM5 (0.72) | CHRM5CHRM3ALDH1A1TDP1KDM4E | |
| SCHEMBL7721235 | 0.84 | CHRM5 (0.72) | CHRM5CHRM3ALDH1A1TDP1KDM4E | |
| SCHEMBL13417680 | 0.82 | CHRM5 (0.70) | CHRM5CHRM3ALDH1A1TDP1KDM4E | |
| SCHEMBL18811886 | 0.79 | CHRM5 (0.66) | CHRM5CHRM3ALDH1A1TDP1KDM4E | |
| SCHEMBL18811738 | 0.79 | CHRM5 (0.66) | CHRM5CHRM3ALDH1A1TDP1KDM4E | |
| SCHEMBL2629206 | 0.79 | SIGMAR1 (0.66) | CHRM5CHRM3ALDH1A1TDP1KDM4E | |
| SCHEMBL20328825 | 0.79 | CHRM5 (0.66) | CHRM5CHRM3ALDH1A1TDP1KDM4E | |
| SCHEMBL6692168 | 0.79 | ALDH1A1 (0.42) | CHRM5CHRM3ALDH1A1TDP1KDM4E | |
| SCHEMBL4969 | 0.79 | ALDH1A1 (0.39) | CHRM5CHRM3ALDH1A1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987252-B2 | Aryloxy- and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-03-24 | — | — | US | claimed |
| US-7956050-B2 | Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-06-07 | — | — | US | claimed |
| US-20100210624-A1 | ARYLOXY- AND HETEROARYLOXY-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-08-19 | — | — | US | claimed |
| EP-2146720-A1 | ARYLOXY-AND HETEROARYLOXY-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR Technology, Inc. (US) | 2010-01-27 | — | — | EP | claimed |
| WO-2008141082-A1 | ARYLOXY-AND HETEROARYLOXY-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2008-11-20 | — | — | WO | claimed |
| US-20080207595-A9 | Psychological disorders; analgesics; hyperactivity; eating disorders | AMR TECHNOLOGY, INC. (US) | 2008-08-28 | — | — | US | claimed |
| EP-1904069-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR Technology, Inc. (US) | 2008-04-02 | — | — | EP | claimed |
| EP-1144384-B1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2007-10-31 | — | — | EP | claimed |
| WO-2007011820-A2 | ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | AMR TECHNOLOGY, INC. (US) | 2007-01-25 | — | — | WO | claimed |
| US-20070021408-A1 | Psychological disorders; analgesics; eating disorders; drug abuse | AMR TECHNOLOGY, INC. (US) | 2007-01-25 | — | — | US | claimed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11628160-B2 | Compositions and methods for treating brain injury | AZEVAN PHARMACEUTICALS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | AZEVAN PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-1112266-B1 | SUBSTITUTED 4-AMINO-2-ARYL-PYRIMIDINES, THEIR PRODUCTION AND USE AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME | AVENTIS PHARMA GMBH (DE) | 2003-05-14 | — | — | EP | disclosed |
| US-6479492-B1 | TREATMENT OF INFLAMMATORY DISEASES IN A MAMMALIAN PATIENT | ELAN PHARMACEUTICALS, INC. | 2002-11-12 | — | — | US | disclosed |
| EP-0708770-B1 | AMIDE DERIVATIVES OF 16-MEMBERED RING ANTIBIOTIC MACROLIDES | PFIZER (US) | 1997-04-16 | — | — | EP | disclosed |
| US-5217971-A | Anticoagulants, hypotensive agents, antiallergens and antiinflammatory agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-08 | — | — | US | disclosed |
| EP-0377457-A1 | Thiazole compounds, processes for the preparation thereof, and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | CHRM5 1450/4885CHRM3 1110/4885ALDH1A1 1429/4885 |
| US-20100210624-A1 | ARYLOXY- AND HETEROARYLOXY-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN | ADRA2B, HTR2B, ADRA1B | CHRM5 141/4885CHRM3 243/4885ALDH1A1 438/4885 |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | GPX4, CRH, TXN | CHRM5 1888/4885CHRM3 1882/4885ALDH1A1 1136/4885 |
| US-20080207595-A9 | Psychological disorders; analgesics; hyperactivity; eating disorders | OPRL1, HTR1B, HTR3C | CHRM5 1208/4885CHRM3 2670/4885ALDH1A1 587/4885 |
| US-20070021408-A1 | Psychological disorders; analgesics; eating disorders; drug abuse | OPRD1, OPRK1, OPRL1 | CHRM5 1586/4885CHRM3 3314/4885ALDH1A1 533/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | CHRM5 322/4885CHRM3 293/4885ALDH1A1 3383/4885 |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | CHRM5 322/4885CHRM3 293/4885ALDH1A1 3383/4885 |
| US-11628160-B2 | Compositions and methods for treating brain injury | FABP7, PYGB, CHAT | CHRM5 1450/4885CHRM3 1110/4885ALDH1A1 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.